• PND62 China Adelphi Abstract

    Jun 1, 2021, 00:00

  • PCV33 Effectiveness of Sacubitril/Valsartan Versus Enalapril in Reducing Mortality and Hospitalizations Costs from an Algerian Hospital Perspective

    Jun 1, 2021, 00:00

  • PMU45 The Impact of COVID-19 on Patient Management across the EU and US

    Jun 1, 2021, 00:00

  • PCV40 Cardiovascular Outcomes Associated with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

    Jun 1, 2021, 00:00

  • Multiple Diseases - Conceptual Papers (CP)

    Jun 1, 2021, 00:00

  • Mental Health - Health Technology Assessment

    Jun 1, 2021, 00:00

  • Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations [Editor's Choice]

    Jun 1, 2021, 00:00

  • PMS11 Explaining the Excess Healthcare Expenditures Associated with Chronic Pain among Adults with Osteoarthritis: An Application of Cost Decomposition Analysis

    Jun 1, 2021, 00:00

  • PND12 Cost-Effectiveness of Fremanezumab for the Treatment of Migraine in England From a Healthcare System Perspective

    Jun 1, 2021, 00:00

  • Rare Orphan Diseases - Health Technology Assessment

    Jun 1, 2021, 00:00

  • PMH5 Budget Impact of reSET-O With Treatment-as-Usual (TAU) vs TAU Alone For The Treatment of Opioid Use Disorder (OUD) Over 5 Years

    Jun 1, 2021, 00:00

  • PDB47 Patients’ Preferences for Antihyperglycemic Medications for Type 2 Diabetes: A Systematic Review of Discrete Choice Experiment

    Jun 1, 2021, 00:00

  • Individual's Health - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • Mental Health - Economic Evaluation

    Jun 1, 2021, 00:00

  • PCN4 Carfilzomib in Combination with Dexamethasone (Kd) Versus Pomalidomide in Combination with Bortezomib and Dexamethasone (PVd): A Matching Adjusted Indirect Treatment Comparison (MAIC)

    Jun 1, 2021, 00:00

  • PSY18 Validation of AAPPO Questionnaire in Adults and Adolescents with Alopecia Areata

    Jun 1, 2021, 00:00

  • Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PNS119 Real-World Evidence Generation in Japan - Uses and Challenges

    Jun 1, 2021, 00:00

  • PCN241 Treatment Pattern and Healthcare Resource Utilization (HRU) in Patients with Metastatic Urothelial Carcinoma (MUC) Among Medicare Fee-for-Service (FFS) Beneficiaries: Results from IMPACT UC

    Jun 1, 2021, 00:00

  • PSY14 Disparities in Targeted Immune Modulating (TIM) Treatment for Elderly Compared to Younger Patients with Psoriatic Arthritis (PSA); Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)

    Jun 1, 2021, 00:00

  • PIN83 The COVID-19 Research Database: Building One of the Largest PRO Bono Real-World DATA Repositories

    Jun 1, 2021, 00:00

  • PRO59 Patient and Parent Preferences for Symptom Control in ASMD Type B and A/B Using Best-Worst Scaling Methodology

    Jun 1, 2021, 00:00

  • PDB10 Differences in Costing Methods in Bariatric Surgery in Chile: DRG Strategy and Bottom up Strategy.

    Jun 1, 2021, 00:00

  • PNS40 Socioeconomic Factors and Insurance Coverage As Predictors of Access to Healthcare Among Women in Ethiopia

    Jun 1, 2021, 00:00

  • PNS88 Classifying High Medical Expenditure Patients Using Logistic Regression and Random Forest Methods

    Jun 1, 2021, 00:00

  • PIN32 A Systematic Literature Review of the Economic Burden of Hospitalized Adults with COVID-19 in Europe and Asia

    Jun 1, 2021, 00:00

  • PMS24 Decision-Making and Benefit-Risk Tradeoffs for Duchenne Muscular Dystrophy Treatment

    Jun 1, 2021, 00:00

  • PMU65 A Systematic Review of the impact of Response Shift on Reporting Patient-Reported Outcomes (PRO) Change over Time in Randomized Clinical Trials

    Jun 1, 2021, 00:00

  • PNS34 Analysis of Structure of E-Prescriptions in Program «Affordable Medicines»

    Jun 1, 2021, 00:00

  • PNS78 Impact of COVID on Health Technology Assessment bodies

    Jun 1, 2021, 00:00

  • PCN95 Effect of Earlier Use of Ibrutinib on Healthcare Resource Utilization (HRU) and Costs Among Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in the United States

    Jun 1, 2021, 00:00

  • SM3 A Technique for Meta-Analysis DATA Extraction with Time-Dependent Outcomes: A Hierarchical Approach

    Jun 1, 2021, 00:00

  • PCN112 Cyclin Dependent Kinase (CDK) 4/6 Inhibitors and LUNG Inflammation: An Analysis of the United States FOOD and Drug Administrations' Adverse Event Reporting System

    Jun 1, 2021, 00:00

  • PRO55 Impact of Cold Agglutinin Disease and Its Related Fatigue on Patients' Daily Life: An Online Survey Among 50 US Patients

    Jun 1, 2021, 00:00

  • PIN22 A Systematic Literature Review of the Economic Burden of Hospitalized Adults with COVID-19 in the USA

    Jun 1, 2021, 00:00

  • PCN89 Estimating the costs of the management of non-HodgkinÂ’s lymphoma at a tertiary health institution

    Jun 1, 2021, 00:00

  • Rare Orphan Diseases - Economic Evaluation

    Jun 1, 2021, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Epidemiology Public Health

    Jun 1, 2021, 00:00

  • PMH37 Do Education Costs Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector.

    Jun 1, 2021, 00:00

  • PNS103 Exposure and Experience with the Ispor Competencies Framework in Heor Fellowships in the United States

    Jun 1, 2021, 00:00

  • PND17 Cost-Effectiveness and Budget Impact of Perampanel Versus Lacosamide As Adjunctive Treatment for Patients with Partial-Onset Seizures in China

    Jun 1, 2021, 00:00

  • PCN210 Patient-Reported Outcomes in Commercial Pediatric Oncology Clinical Trials

    Jun 1, 2021, 00:00

  • PCN195 Estimating Correlation between PFS and OS from Reconstructed Survival Data: A Case Study from Previously Untreated Glioblastoma Multiforme

    Jun 1, 2021, 00:00

  • PIN2 Prevalence and Factors Associated with Redundant Antibiotic Therapy Among Inpatients

    Jun 1, 2021, 00:00

  • PNS113 Translation and Cultural Adaptation of the Telemedicine Satisfaction Questionnaire for Use in Romania

    Jun 1, 2021, 00:00

  • PND39 Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Relapsing Remitting Multiple Sclerosis

    Jun 1, 2021, 00:00

  • Respiratory-Related Disorders - Epidemiology Public Health

    Jun 1, 2021, 00:00

  • PGI15 Comparison of Burden of Hospitalizations in Ulcerative Colitis (UC) and Crohn's Disease (CD) Patients with and without Surgery: A Propensity Score Matched Analysis of In-Patient Claims Database

    Jun 1, 2021, 00:00

  • PSS13 Evaluation of Sociodemographic Characteristics, Perceived Vision Impairment, and Functional Status in Patients With Retinal Disease: Analysis of the Medicare Current Beneficiary Survey (MCBS) Data

    Jun 1, 2021, 00:00

  • PNS80 Assessment of Prognostic and Predictive tests by the NICE Diagnostics Assessment Programme

    Jun 1, 2021, 00:00

  • PIN47 COVID-19 Patient Severities in Japanese EMR

    Jun 1, 2021, 00:00

  • PCN50 Cost of Chronic Myeloid Leukemia Care Among Patients in Advanced Phases or on Later Lines of Therapy in Chronic Phase in the United States From a Commercial and Medicare Perspective

    Jun 1, 2021, 00:00

  • PCN186 Recommendations for Colon Cancer (CC) Screening in Individuals with Average Risk Based on Immunochemical Fecal Occult Blood Test (IFOBT) in Argentina Using GRADE-Adolopment Tool

    Jun 1, 2021, 00:00

  • PIN26 Lifetime cost estimation of human papillomavirus related diseases in China: a modelling study using real-world data

    Jun 1, 2021, 00:00

  • PCV27 Hospital Length of Stay, Total Costs and Comorbidities in Patients with Acute Pericarditis: Analysis of National In-patient Hospital Database

    Jun 1, 2021, 00:00

  • PGI26 Current Landscape and Treatments USED in Patients with Moderate-to-Severe Ulcerative Colitis

    Jun 1, 2021, 00:00

  • PDG11 A Cost-Comparative Analysis of Outpatient Use of Intravenous Ferric Carboxymaltose Versus Intravenous Iron Sucrose in a Major Tertiary Care Hospital in Saudi Arabia

    Jun 1, 2021, 00:00

  • PMD15 Surgical Treatment, Reoperations, and Complications among Patients with Clavicle Fracture in England

    Jun 1, 2021, 00:00

  • PB3 Real World Adherence, Persistence, Relapse and Multiple Sclerosis Symptoms Among Patients Treated with Oral Disease-Modifying Therapies

    Jun 1, 2021, 00:00

  • PCN190 Budget Impact of the DiviTum®Tka Assay in Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer

    Jun 1, 2021, 00:00

  • PDG18 Coverage of the Opioid Crisis in National Network Television News from 2000-2020: A Content Analysis

    Jun 1, 2021, 00:00

  • PMH2 Patient Profiles and Hospital Re-encounters of Patients with a Hospital Emergency Department Visit or Inpatient Admission for Major Depressive Disorder

    Jun 1, 2021, 00:00

  • PDB8 Changes in Cost of ORAL Antidiabetic Drugs By Introduction of Formularies in JAPAN: A Simulation Using Health Insurance Claims Database

    Jun 1, 2021, 00:00

  • 10 Years of End-of-Life Criteria in the United Kingdom [Editor's Choice]

    May 1, 2021, 00:00

  • Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic [Editor's Choice]

    May 1, 2021, 00:00

  • Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies

    May 1, 2021, 00:00

  • Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA’s Health Technology Assessments [Editor's Choice]

    May 1, 2021, 00:00

  • HIV Pre-Exposure Prophylaxis, Condoms, or Both? Insights on Risk Compensation Through a Discrete Choice Experiment and Latent Class Analysis Among Men Who Have Sex With Men

    May 1, 2021, 00:00

  • Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands

    May 1, 2021, 00:00

  • Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs

    May 1, 2021, 00:00

  • Copyright/Subscription

    May 1, 2021, 00:00

  • Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response

    May 1, 2021, 00:00

  • Smoking Cessation and Quality of Life: Insights From Analysis of Longitudinal Australian Data, an Application for Economic Evaluations

    May 1, 2021, 00:00

  • A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies

    May 1, 2021, 00:00

  • How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? [Editor's Choice]

    May 1, 2021, 00:00

  • Table of Contents

    May 1, 2021, 00:00

  • Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial

    May 1, 2021, 00:00

  • Joint Longitudinal Models for Dealing With Missing at Random Data in Trial-Based Economic Evaluations

    May 1, 2021, 00:00

  • A Head-to-Head Comparison of the Standard Quality-Adjusted Life Year Model With the Annual Profile Model [Editor's Choice]

    May 1, 2021, 00:00

  • Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States

    May 1, 2021, 00:00

  • Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands

    May 1, 2021, 00:00

  • Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study

    May 1, 2021, 00:00

  • Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis

    May 1, 2021, 00:00

  • Editorial Board

    Apr 29, 2021, 10:55

  • Editorial Board

    Apr 8, 2021, 17:09

  • A Real-World Comparison of 1-Year Survival and Expenditures for Transcatheter Aortic Valve Replacements: SAPIEN 3 Versus CoreValve Versus Evolut R

    Apr 1, 2021, 00:00

  • Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management

    Apr 1, 2021, 00:00

  • An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis [Editor's Choice]

    Apr 1, 2021, 00:00

  • Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review

    Apr 1, 2021, 00:00

  • Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making

    Apr 1, 2021, 00:00

  • A Value Framework for the Assessment of Diagnostic Technologies: A Proposal Based on a Targeted Systematic Review and a Multistakeholder Deliberative Process in Latin America [Editor's Choice]

    Apr 1, 2021, 00:00

  • Economic Consequences of Adult Living Kidney Donation: A Systematic Review

    Apr 1, 2021, 00:00

  • Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report [Editor's Choice]

    Apr 1, 2021, 00:00

  • International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects

    Apr 1, 2021, 00:00

  • Evidence of Quantitative Measures of Preferences Over Health States in Schizophrenia

    Apr 1, 2021, 00:00

  • Author Reply

    Apr 1, 2021, 00:00

  • Development and Validation of a Hospital Indicator of Activity-Based Costs for Injury Admissions

    Apr 1, 2021, 00:00

  • Copyright/Subscription

    Apr 1, 2021, 00:00

  • Late Pregnancy Ultrasound to Screen for and Manage Potential Birth Complications in Nulliparous Women: A Cost-Effectiveness and Value of Information Analysis

    Apr 1, 2021, 00:00

  • Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey

    Apr 1, 2021, 00:00

  • Cost-Effectiveness Analysis of Transcatheter Arterial Embolization Techniques for the Treatment of Gastrointestinal Bleeding in the United States

    Apr 1, 2021, 00:00

  • Engaging the Voices of Children: A Scoping Review of How Children and Adolescents Are Involved in the Development of Quality-of-Life–Related Measures [Editor's Choice]

    Apr 1, 2021, 00:00

  • Attribute Selection for a Discrete Choice Experiment Incorporating a Best-Worst Scaling Survey

    Apr 1, 2021, 00:00

  • Table of Contents

    Apr 1, 2021, 00:00

  • Friction Costs and the Chain of Vacancies Problem: A Novel Vacancy Multiplier Solution [Editor's Choice]

    Apr 1, 2021, 00:00

  • Evaluating the Cost-Effectiveness of Changes to the Surveillance Intervals in the UK Abdominal Aortic Aneurysm Screening Programme

    Mar 1, 2021, 00:00

  • Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis

    Mar 1, 2021, 00:00

  • Copyright/Subscription

    Mar 1, 2021, 00:00

  • A Big WIN in Texas: Demonstrating the Benefits of Patient Self-Efficacy and Patient Activation

    Mar 1, 2021, 00:00

  • Childhood Nutrition in Rural China: What Impact Does Public Health Insurance Have?

    Mar 1, 2021, 00:00

  • Cost-Effectiveness of the Wellness Incentives and Navigation (WIN) Program

    Mar 1, 2021, 00:00

  • When Industrial Policies Conflict With Population Health: Potential Impact of Removing Food Subsidies on Obesity Rates

    Mar 1, 2021, 00:00

  • Table of Contents

    Mar 1, 2021, 00:00

  • Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs

    Mar 1, 2021, 00:00

  • Preferences for e-Mental Health Interventions in Germany: A Discrete Choice Experiment

    Mar 1, 2021, 00:00

  • The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What “Cost” to Patients?

    Mar 1, 2021, 00:00

  • A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health [Editor's Choice]

    Mar 1, 2021, 00:00

  • Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate

    Mar 1, 2021, 00:00

  • A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults

    Mar 1, 2021, 00:00

  • Fundamental Measurement and Quality-Adjusted Life Years

    Mar 1, 2021, 00:00

  • Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison [Editor's Choice]

    Mar 1, 2021, 00:00

  • Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

    Mar 1, 2021, 00:00

  • Nutrition Economics: Celebrating Cross-Disciplinary Collaboration

    Mar 1, 2021, 00:00

  • A Patient-Centric Tool to Facilitate Goal Attainment Scaling in Neurogenic Bladder and Bowel Dysfunction: Path to Individualization

    Mar 1, 2021, 00:00

  • Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening

    Mar 1, 2021, 00:00

  • Editorial Board

    Feb 25, 2021, 08:47

  • Editorial Board

    Feb 22, 2021, 21:25

  • Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review

    Feb 1, 2021, 00:00

  • Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries

    Feb 1, 2021, 00:00

  • Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening

    Feb 1, 2021, 00:00

  • Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach [Editor's Choice]

    Feb 1, 2021, 00:00

  • Opioid Misuse: A Global Crisis

    Feb 1, 2021, 00:00

  • Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis [Editor's Choice]

    Feb 1, 2021, 00:00

  • Economic Evaluation in Opioid Modeling: Systematic Review [Editor's Choice]

    Feb 1, 2021, 00:00

  • Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes

    Feb 1, 2021, 00:00

  • Utility Decrements Associated With Diabetes and Related Complications: Estimates From a Population-Based Study in Germany

    Feb 1, 2021, 00:00

  • Table of Contents

    Feb 1, 2021, 00:00

  • A Systematic Review and Meta-Analysis of Change in Health-Related Quality of Life for Interactive Telehealth Interventions for Patients With Asthma

    Feb 1, 2021, 00:00

  • Cost-Effectiveness of Providing the Depression Care for People With Cancer Program to Patients With Prostate Cancer in the United States

    Feb 1, 2021, 00:00

  • Incidence and Variables Associated With Inconsistencies in Opioid Prescribing at Hospital Discharge and Its Associated Adverse Drug Outcomes

    Feb 1, 2021, 00:00

  • Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index [Editor's Choice]

    Feb 1, 2021, 00:00

  • Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018

    Feb 1, 2021, 00:00

  • Burden of Providing Informal Care for Patients with Atrial Fibrillation

    Feb 1, 2021, 00:00

  • Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products

    Feb 1, 2021, 00:00

  • Copyright/Subscription

    Feb 1, 2021, 00:00

  • Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis

    Feb 1, 2021, 00:00

  • Cost-Effectiveness of an Opioid Abuse–Prevention Program Using the Narcotics Information Management System in South Korea

    Feb 1, 2021, 00:00

  • Editorial Board

    Jan 12, 2021, 17:42

  • Consultations for Influenza-Like Illness in Primary Care in The Netherlands: A Regression Approach

    Jan 1, 2021, 00:00

  • What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries

    Jan 1, 2021, 00:00

  • Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018 [Editor's Choice]

    Jan 1, 2021, 00:00

  • Distributional Cost-Effectiveness Analysis Comes of Age [Editor's Choice]

    Jan 1, 2021, 00:00

  • Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review

    Jan 1, 2021, 00:00

  • Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany

    Jan 1, 2021, 00:00

  • Copyright/Subscription

    Jan 1, 2021, 00:00

  • Cost-Utility Analysis of a Complex Intervention to Reduce School-Based Bullying and Aggression: An Analysis of the Inclusive RCT

    Jan 1, 2021, 00:00

  • Table of Contents

    Jan 1, 2021, 00:00

  • Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program

    Jan 1, 2021, 00:00

  • What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model

    Jan 1, 2021, 00:00

  • Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease

    Jan 1, 2021, 00:00

  • Integrating Alternative Social Value Judgments Into Cost-Effectiveness Analysis of Vaccines: An Application to Varicella-Zoster Virus Vaccination

    Jan 1, 2021, 00:00

  • Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands

    Jan 1, 2021, 00:00

  • Health Economics of Vaccines: From Current Practice to Future Perspectives [Editor's Choice]

    Jan 1, 2021, 00:00

  • Instructions for Authors

    Jan 1, 2021, 00:00

  • Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis

    Jan 1, 2021, 00:00

  • Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?

    Jan 1, 2021, 00:00

  • Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective

    Jan 1, 2021, 00:00

  • Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction? [Editor's Choice]

    Jan 1, 2021, 00:00

  • Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches

    Jan 1, 2021, 00:00

  • Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients

    Jan 1, 2021, 00:00

  • Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030

    Jan 1, 2021, 00:00

  • PCN25 First Real-World Evidence of Immunotherapy in the Brazilian Public Health System: A Retrospective Study in Melanoma Patients Treated with Pembrolizumab

    Dec 1, 2020, 00:00

  • PCN34 Associations between Transfusion Status and Clinical, Economic, and Humanistic Outcomes in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2020, 00:00

  • PBI39 Price Determinants in Tenders for Biotechnological Drugs with Expired Patents in Italy: An Empirical Analysis

    Dec 1, 2020, 00:00

  • PCN111 Cost-Effectiveness Analysis of Ixazomib PLUS Lenalidomide-Dexamethasone Versus Daratumumab PLUS Lenalidomide-Dexamethasone in Multiple Myeloma Patients Received More THAN One PRIOR Treatment in China

    Dec 1, 2020, 00:00

  • PBI31 A Reimbursement LAG Analysis to Understand How EARLY WAS CAR T-Cell Therapy Reimbursed across Europe

    Dec 1, 2020, 00:00

  • PCN119 Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy and Blinatumomab for Treating Relapsed Refractory ACUTE Lymphoblastic Leukaemia Patients in the Netherlands

    Dec 1, 2020, 00:00

  • PBI56 Psychometric Validation of the P-SIM, a NOVEL Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis

    Dec 1, 2020, 00:00

  • PBI34 Paying for Curative GENE Therapies: Potential, Barriers and Healthcare Reforms for Risk-Sharing between Payers and Industry in a MULTI-Payer Healthcare System

    Dec 1, 2020, 00:00

  • ML2 Network Meta-Analysis (NMA) Powered By Artificial Intelligence

    Dec 1, 2020, 00:00

  • PCN37 First LINE Treatment in DLBCL Patients: An Italian Cancer Centre Experience in a Real-Word Setting

    Dec 1, 2020, 00:00

  • PCN77 Disease Burden of Chronic Lymphoid Leukemia (CLL) in Fran A Descriptive Study Based on a French Medico-Administrative Database

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Patient-Centered Research

    Dec 1, 2020, 00:00

  • Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic Model

    Dec 1, 2020, 00:00

  • PCN39 Impact of Medication Non-Adherence on Hard Clinical Endpoints in Patients with Breast Cancer: Results of a Systematic Literature Review

    Dec 1, 2020, 00:00

  • PCN55 Budget IMPACT of Implementing HPV Testing in Cervical Cancer Screening in Austria - a MODEL Based Analysis

    Dec 1, 2020, 00:00

  • Comprehensive Benefit–Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis

    Dec 1, 2020, 00:00

  • CL3 Efficiency of Triage By a Rheumatologist in Primary Care for Patients Suspect for Inflammatory Arthritis: Preliminary Results

    Dec 1, 2020, 00:00

  • PBI18 Efficiency of Innovative Biologics Indicated for Moderate-Severe Psoriasis

    Dec 1, 2020, 00:00

  • PA4 Delaying Assistance Intensification Among Elderly with Assisted Living Services: Care Costs, Target Group Profile, and IMPACT Estimation for a Potential Social IMPACT Bond (SIB) in Finland

    Dec 1, 2020, 00:00

  • PCN87 Budget IMPACT Analysis of the Use of Transdermal Buprenorphine VS Morphine Hydrochloride in Cancer PAIN from the Perspective of the Public Health System in Colombia

    Dec 1, 2020, 00:00

  • MT4 The Cost-Effectiveness of Selective Internal Radiation Therapy (SIRT) for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom

    Dec 1, 2020, 00:00

  • Measuring Quality-Adjusted Life-Years When Health Fluctuates

    Dec 1, 2020, 00:00

  • Donor Kidney Quality and Transplant Outcome: An Economic Evaluation of Contemporary Practice

    Dec 1, 2020, 00:00

  • PCN92 Cost Effectiveness of Obinutuzumab PLUS Chemotherapy Followed By Obinutuzumab Maintenance for Patient with Previously Untreated Advanced-STAGE Follicular Lymphoma in French Setting

    Dec 1, 2020, 00:00

  • PCN16 External Control Analysis of Overall Survival in BRAFV600 Mutated Metastatic NSCLC: Comparing Single-Arm Dabrafenib+Trametinib Clinical Trial Outcomes with Real-World Standards of Care

    Dec 1, 2020, 00:00

  • PCN35 Treatment and Outcomes in Recurrent Metastatic Squamous CELL Carcinoma of the Head and Neck (R/M SCCHN): A Chart Review Study in France, Germany and the United Kingdom (UK)

    Dec 1, 2020, 00:00

  • PBI17 Cost-Efectiveness Analysis of Biological Agents to Moderate to Severe Plaque Psoriasis Treatmente from the Brazilian Public Health System Perspective

    Dec 1, 2020, 00:00

  • PCN27 Treatment Outcomes and Healthcare Resources Utilization of Palbociclib in Advanced Breast Cancer

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Clinical Outcomes

    Dec 1, 2020, 00:00

  • PCN134 Heterogeneity Considerations in Economic Analyses of Cancer

    Dec 1, 2020, 00:00

  • PCN15 DATA Transparency in Oncology – a Quantitative Analysis of Outcome Results in Amnog Documents and Clinicaltrials.Gov

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    Dec 1, 2020, 00:00

  • PBI19 Cost-Effectiveness Analysis of Adalimumab Biosimilar for Rheumatoid Arthritis in Brazil Compared to Delayed Biologic Treatment Initiation

    Dec 1, 2020, 00:00

  • PCN36 Systematic Review of Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC) with DNA Damage Repair Gene Mutation (DDRm)

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    Dec 1, 2020, 00:00

  • MT3 A Review of the National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance over the Last 10 YEARS

    Dec 1, 2020, 00:00

  • Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?

    Dec 1, 2020, 00:00

  • HTA4 Clinical Development and HTA Approval of MULTI-Indication Oncology Products: Evidence from Germany, France, England, Scotland, the US, Canada, and Australia

    Dec 1, 2020, 00:00

  • Evaluation of Care Pathways

    Dec 1, 2020, 00:00

  • PBI16 Betibeglogene Autotemcel GENE Therapy (BETI-CEL) Is Cost-Effective Versus Standard of Care in Patients with Transfusion-Dependent B-Thalassemia (TDT) in France

    Dec 1, 2020, 00:00

  • Predicting the Effects of the COVID-19 Pandemic and Designing Effective Interventions

    Dec 1, 2020, 00:00

  • Table of Contents

    Dec 1, 2020, 00:00

  • CO4 An Evaluation of the Differences in Vaccine Approval and Procurement Processes between Healthcare Systems during a Pandemic

    Dec 1, 2020, 00:00

  • PCN114 Real-World Healthcare Costs Of Late-Line Multiple Myeloma (MM) Patients On Common Monotherapies: A German Claims Data Analysis

    Dec 1, 2020, 00:00

  • PCN46 A Conceptual Framework for the Approach to the Evaluation of Oncology Survival Benefit in Health Technology Assessment

    Dec 1, 2020, 00:00

  • Nature and Predictors of Response Changes in Modified-Delphi Panels (Editor's Choice)

    Dec 1, 2020, 00:00

  • PCN116 Economic Impact of First-Line (1L) Immunotherapies in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2020, 00:00

  • Modelling and Simulation Methods

    Dec 1, 2020, 00:00

  • PA3 New Primary Care Incentive Scheme for Type 2 Diabetes in Denmark

    Dec 1, 2020, 00:00

  • PCN22 Real-World Effectiveness of Eribulin in the Patients with Metastatic Breast Cancer: Evidence from Single Medication Center in Taiwan

    Dec 1, 2020, 00:00

  • PCN29 Time to Next Treatment As a Candidate Surrogate Endpoint for Overall Survival in Previously Untreated Advanced Melanoma Patients Treated with Immune-Checkpoint Inhibitors

    Dec 1, 2020, 00:00

  • PCN41 Overall Complete Remission Rate (OCRR) and Complete Remission Rate (CR) of Standard of Care (SoC) in Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Meta-Analysis

    Dec 1, 2020, 00:00

  • PCN112 Estimating Resources Utilization and Health Care Costs Related to Colorectal Cancer Patients in Saudi Arabia

    Dec 1, 2020, 00:00

  • Machine Learning Improves the Identification of Individuals With Higher Morbidity and Avoidable Health Costs After Acute Coronary Syndromes

    Dec 1, 2020, 00:00

  • Cancer - Conceptual Papers (CP)

    Dec 1, 2020, 00:00

  • Extrapolation Methods

    Dec 1, 2020, 00:00

  • PBI58 Persistence of Treatment with Biologics for Patients with Psoriasis: An Analysis of a French Prescription Database

    Dec 1, 2020, 00:00

  • PCN61 Healthcare Costs Comparison of Nivolumab Versus Placebo As Adjuvant Treatment of Patients with Melanoma: A Propensity Score Matched Analysis

    Dec 1, 2020, 00:00

  • EX3 Investigating Time to Next Treatment As a Surrogate Endpoint for Overall Survival in Previously Untreated Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma Patients: An Insight from the Phase III CheckMate-214

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Epidemiology Public Health

    Dec 1, 2020, 00:00

  • PCN124 Health Utilities for Patients with HR-Positive, HER2-Negative EARLY Breast Cancer: A Systematic Literature Review

    Dec 1, 2020, 00:00

  • PCN135 Considerations of Heterogeneity in Resource Use and Health Utility Quantification in Economic Analyses of Cancer

    Dec 1, 2020, 00:00

  • Estimating Cost Functions for Resource Allocation Using Transmission Models: A Case Study of Tuberculosis Case Finding in South Africa

    Dec 1, 2020, 00:00

  • Reviewer Acknowledgement

    Dec 1, 2020, 00:00

  • PCN79 IMPACT of Adjuvant Trastuzumab Emtansine (T-DM1) on the Incidence of HER2-Positive Metastatic Breast Cancer and Its Associated Savings for the Spanish National Healthcare System

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Policy Regulatory

    Dec 1, 2020, 00:00

  • Copyright/Subscription

    Dec 1, 2020, 00:00

  • PBI49 A Comparative Analysis of Cost-Effectiveness Evaluations of Cell and GENE Therapies across HTA Organisations

    Dec 1, 2020, 00:00

  • IN3 Impact of Government Measures on COVID-19 Incidence of Reported New Cases: An Analysis of 9 Countries

    Dec 1, 2020, 00:00

  • PCN121 A Systematic Literature Review of Pharmacoeconomic Evaluations for Chronic Lymphocytic Leukemia in Europe

    Dec 1, 2020, 00:00

  • PBI33 Investigating Potential Market Failure with Curative Cell and GENE Therapies

    Dec 1, 2020, 00:00

  • PCN88 Systematic Literature Review (SLR) of Economic and Healthcare Resource Utilization Evidence in the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

    Dec 1, 2020, 00:00

  • PCN95 Clinical and Economic IMPACT of ALK Rearrangement Testing in Advanced NSCLC in Spain Compared with a Hypothetical NO-Testing Scenario

    Dec 1, 2020, 00:00

  • PBI15 The Economic Burden for the Management of Moderate-to-Severe Psoriasis in the Kingdom of Saudi Arabia

    Dec 1, 2020, 00:00

  • PCN66 Cost-Effectiveness Model Adapted to Italian Clinical Practice for Evaluation of Entrectinib Versus Crizotinib in ROS1+ NSCLC Patients

    Dec 1, 2020, 00:00

  • PCN38 Health-Related Quality of Life (QOL) in Monarch PLUS: A Phase 3 Trial of Abemaciclib PLUS Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant for Women with HR+/HER2- Advanced Breast Cancer (ABC)

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Medical Technologies

    Dec 1, 2020, 00:00

  • PCN105 Comparison of Healthcare Costs in France of Combination Nivolumab and Ipilimumab Treatment Versus Nivolumab Monotherapy and Ipilimumab Monotherapy in Advanced Melanoma

    Dec 1, 2020, 00:00

  • PCN129 Disease Burden of Diffuse Large B-CELL Lymphoma(DLBCL) Patients with or without Hematopoietic STEM CELL Transplantation: A CROSS-Sectional Analysis from Nationwide Claims Cohort DATA

    Dec 1, 2020, 00:00

  • PCN131 Cost-Effectiveness Models and Resource Use/Cost Inputs for Untreated Advanced/Metastatic Renal Cell Carcinoma- A Systematic Literature Review

    Dec 1, 2020, 00:00

  • MS4 How to Assess the Lifetime IMPACT of Lifestyle Interventions for Type 2 Diabetes in Germany? a Markov MODEL Design and Validation

    Dec 1, 2020, 00:00

  • NM2 Using Randomized and Observational DATA to Predict Heterogeneous Treatment Effects

    Dec 1, 2020, 00:00

  • Patient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care (Editor's Choice)

    Dec 1, 2020, 00:00

  • Cancer - Clinical Outcomes

    Dec 1, 2020, 00:00

  • PCN74 Comparing Healthcare Costs in the Last Year of Life Among Patients with Different Cancer Indications in Germany

    Dec 1, 2020, 00:00

  • PCN137 Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening Strategies By Age Range and Frequency Among High-Risk Individuals in Spain

    Dec 1, 2020, 00:00

  • NM4 Flexible Generic Framework for Evidence Synthesis in Health Technology Assessment

    Dec 1, 2020, 00:00

  • PCN96 Economic Burden of BRAIN Metastasis in NON SMALL CELL LUNG Cancer in South Korea: Nationwide Retrospective Cohort Study

    Dec 1, 2020, 00:00

  • PCN17 Health-Related Quality of Life (HRQOL) of ALK-Rearranged NON-SMALL CELL LUNG Cancer (NSCLC) Patients Treated in Second LINE with Alectinib

    Dec 1, 2020, 00:00

  • CO3 Effectiveness of Government Measures to Reduce COVID-19 Mortality across 5 Different Countries

    Dec 1, 2020, 00:00

  • PCN28 Relationship between Surrogate Endpoints and Overall Survival in Studies That Prohibited Crossover or Reported Balanced Post-Progression Treatments; Pooled Analysis in Advanced NSCLC Patients

    Dec 1, 2020, 00:00

  • PBI53 Initiation of Ixekizumab in Patients with Psoriasis and Follow-up Assessment in the Badbir Registry

    Dec 1, 2020, 00:00

  • PBI13 Budget Impact Analysis to Assess The Impact of Adalimumab-atto (Biosimilar) Compared to Adalimumab in Autoimmune Diseases in United Arab Emirates

    Dec 1, 2020, 00:00

  • PCN84 Preliminary Results of a Cost Effectiveness MODEL of Atezolizumab PLUS Bevacizumab in Unresectable Hepatocellular Carcinoma (HCC) in France

    Dec 1, 2020, 00:00

  • Clinical Outcomes Assessment Studies

    Dec 1, 2020, 00:00

  • PCN21 Efficacy and Safety in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update

    Dec 1, 2020, 00:00

  • PCN103 Cost-Effectiveness Analysis of Trastuzumab Emtansine for Adjuvant Treatment of Adult Patients with HER2+ EARLY Breast Cancer in Turkey

    Dec 1, 2020, 00:00

  • Editorial Board

    Dec 1, 2020, 00:00

  • Issues in HEOR - Oncology

    Dec 1, 2020, 00:00

  • CL4 Concerns, Quality of Life, Access to Care and Productivity of the General Population during the First 8 WEEKS of the Coronavirus Lockdown in Belgium and the Netherlands

    Dec 1, 2020, 00:00

  • Economic Evaluations in National Cancer Institute–Sponsored Network Cancer Clinical Trials

    Dec 1, 2020, 00:00

  • PCN132 Cost-Effectiveness Analysis of RE-Treatment with 177lu-Dotatate Versus NO RE-Treatment with 177lu-Dotatate in Patients with Progressive Midgut Neuroendocrine Tumors

    Dec 1, 2020, 00:00

  • Network Meta-Analysis: Advances in Methodology and Practice

    Dec 1, 2020, 00:00

  • Preferences for Accessing Electronic Health Records for Research Purposes: Views of Parents Who Have a Child With a Known or Suspected Genetic Condition

    Dec 1, 2020, 00:00

  • PBI22 Rethinking the Health-Economic Evaluation Framework for GENE Therapies: The Betibeglogene Autotemcel (BETI-CEL) Case in Î’-Thalassemia

    Dec 1, 2020, 00:00

  • MS3 Reproduction of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Barriers

    Dec 1, 2020, 00:00

  • PBI9 Treatment Sequencing in Modeling the Economic Benefits of Psoriasis Therapy: IMPACT of Key Assumptions

    Dec 1, 2020, 00:00

  • PCN127 Cost per Outcome Analysis of Nivolumab Versus Dabrafenib+Trametinib As Adjuvant Therapy for Patients with STAGE Iiib/C BRAF-Mutant Cutaneous Melanoma in Spain

    Dec 1, 2020, 00:00

  • PCN52 New Insights from CAR-T: An Economic and Organizational Perspective

    Dec 1, 2020, 00:00

  • PCN43 Risk of Recurrence Among Patients with HR-Positive, HER2-Negative, EARLY Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review and Meta-Analysis

    Dec 1, 2020, 00:00

  • PCN60 Cost-Effectiveness of Avelumab in the Treatment of Patients with Metastatic Merkel Cell Carcinoma in Portugal

    Dec 1, 2020, 00:00

  • MT2 Discrepancy between the Cost of an Innovative Medical Procedure and Its Payment: The Case of Mechanical Thrombectomy Procedures in ACUTE Ischemic Stroke in France

    Dec 1, 2020, 00:00

  • Cancer - Economic Evaluation

    Dec 1, 2020, 00:00

  • PCN7 Systematic Differences between Embraca and Olympiad Phase III Physician's Choice Chemotherapy (PCT) Arms: A FOCUS on the First-LINE (1L) Treatment of Metastatic Breast Cancer (MBC) Subpopulations

    Dec 1, 2020, 00:00

  • MS2 Methods to Optimise Survival Predictions Using Multistate Models in Oncology

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Conceptual Papers (CP)

    Dec 1, 2020, 00:00

  • EX4 Bayesian MULTI-Parameter Evidence Synthesis to Improve LONG TERM Survival Extrapolation with EARLY Follow up DATA from Nivolumab NSCLC Studies

    Dec 1, 2020, 00:00

  • PCN6 Matching-Adjusted Indirect Treatment Comparisons (MAIC) of the Effect of Lorlatinib Versus Chemotherapy on Overall Survival (OS) and Progression-Free Survival (PFS) for Patients with Second-LINE or Later Anaplastic Lymphoma Kinase (ALK ...

    Dec 1, 2020, 00:00

  • PCN78 Costs of Recurrence in Patients with HER2+ Breast Cancer in Spain

    Dec 1, 2020, 00:00

  • AD2 Qualitative Interviews to Explore Drivers and Behaviours Associated with Medication NON-Adherence across a Range of Diseases, Treatment Modalities, and Countries

    Dec 1, 2020, 00:00

  • PBI45 Reimbursement Pathways and Associated Timelines in European GENE Therapies

    Dec 1, 2020, 00:00

  • PCN44 Systematic Literature Review of Clinical Outcomes, Economic Burden, and Humanistic Burden of Anemia in Patients with Myelodysplastic Syndromes

    Dec 1, 2020, 00:00

  • ON4 Heterogeneity in Survival with Immuno-Oncologic Therapy and Its Implications for Survival Extrapolations: A Case Study in Untreated Metastatic Melanoma

    Dec 1, 2020, 00:00

  • PCN20 Can Real-World Data Replicate RCT Results? A Retrospective Comparative Effectiveness Study Of Docetaxel In Metastatic Hormone Sensitive Prostate Cancer Using German Claims Data

    Dec 1, 2020, 00:00

  • PCN24 Disease-Free Survival (DFS) As a Surrogate Endpoint for Overall Survival (OS) in HER2 Negative (HER2–) Primary Breast Cancer (BC)

    Dec 1, 2020, 00:00

  • PBI2 A Systematic Literature Review (SLR) and EARLY Network Meta-Analysis (ENMA) of Current and Future Treatments for Moderate to Severe Hidradenitis Suppurativa (HS)

    Dec 1, 2020, 00:00

  • PCN108 The Cost-Effectiveness of Liposomal Irinotecan and 5-Fluorouracil (5-FU)/ Leucovorin (LV) for the Treatment of Patients with Metastatic Adenocarcinoma of Pancreas WHO Have Progressed Following the Use of Gemcitabine-Related Therapies ...

    Dec 1, 2020, 00:00

  • PBI12 Budget Impact Analysis of Baricitinib for the Management of Moderate-to-Severe Rheumatoid Arthritis in the Kingdom of Saudi Arabia

    Dec 1, 2020, 00:00

  • Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia

    Dec 1, 2020, 00:00

  • CV4 Patients with Hypercholesterolaemia or MIXED Dyslipidaemia and High or VERY High Cardiovascular Risk According to ESC/EAS Guidelines – a Population-Based CROSS–Sectional Study from the Netherlands

    Dec 1, 2020, 00:00

  • PCN106 A Study to Assess the Impact of Incorporating the ‘Probability of Being in Response Function’ into an Economic Model for Nivolumab in Advanced Renal-Cell Carcinoma

    Dec 1, 2020, 00:00

  • PCN33 Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies

    Dec 1, 2020, 00:00

  • Machine Learning and Artificial Intelligence to Improve Decision-Making in Healthcare

    Dec 1, 2020, 00:00

  • HTA2 Joint HTA in Europe to What Extent Are Reports Meeting Agency NEEDS?

    Dec 1, 2020, 00:00

  • PCN100 Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma in Italy: A Budget Impact Analysis

    Dec 1, 2020, 00:00

  • PCN139 Cost per Consequence Analysis of Erdafinitib and ANTI-PD1/PDL1 Therapies for Metastatic Urothelial Carcinoma FGFR+ from the Perspective of Brazilian Private Health System

    Dec 1, 2020, 00:00

  • Impact of Infectious Diseases on the Wider Health System and Other Sectors

    Dec 1, 2020, 00:00

  • PCN133 Disease Burden of Hodgkin's Lymphoma in Fran A Descriptive Study Based on a French Medico-Administrative Database

    Dec 1, 2020, 00:00

  • PBI43 Treatment Patterns with Targeted Immune Modulators Among Patients with Rheumatoid Arthritis: A Retrospective Analysis of Electronic Health Records in the US

    Dec 1, 2020, 00:00

  • PBI21 The MOST Cost-Effective Approach to Prevent Complications in Young Patients Diagnosed with Sickle CELL Anemia from Employers Perspective Using Decision Tree MODEL

    Dec 1, 2020, 00:00

  • Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis

    Dec 1, 2020, 00:00

  • CL2 Measuring Health-Related Quality of Life in the Context of Episodic Conditions

    Dec 1, 2020, 00:00

  • PCN122 Cost-Effectiveness of Brentuximab Vedotin for the Frontline Treatment of Peripheral T-Cell Lymphomas in Canada

    Dec 1, 2020, 00:00

  • NM3 Extending the Network Meta-Analysis (NMA) Framework to Multilevel Network Meta-Regression (ML-NMR): A Worked Example of ML-NMR VS Standard NMA

    Dec 1, 2020, 00:00

  • PCN53 TREND of Healthcare Costs and Survival Among Patients with LUNG Cancer: A Real-World Italian Study

    Dec 1, 2020, 00:00

  • PCN48 Adapting Preference-Based Utility Measures to Capture the Impact of Cancer Treatment-Related Symptoms

    Dec 1, 2020, 00:00

  • PCN71 Budget IMPACT Analysis of Zanubrutinib for the Treatment of Adult Patients with Mantle Cell Lymphoma WHO Have Received at Least One PRIOR Therapy from the Payer Perspective in the United States

    Dec 1, 2020, 00:00

  • PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

    Dec 1, 2020, 00:00

  • PCN19 Effectiveness and Medical Costs of Abiraterone Acetate Versus Docetaxel in First-LINE Treatment of Metastatic Castration-Resistant Prostate Cancer from the French Nationwide Claims Database (SNDS): Camerra Study

    Dec 1, 2020, 00:00

  • PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France

    Dec 1, 2020, 00:00

  • PBI10 Cost Effectiveness Analysis for the Treatment of Psoriasis: The Use of Adalimumab Biosimilars

    Dec 1, 2020, 00:00

  • Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation (Editor's Choice)

    Dec 1, 2020, 00:00

  • PCN97 Budget IMPACT of Oncotype DX GPS ASSAY in Patients with Localized Prostate Cancer in Germany

    Dec 1, 2020, 00:00

  • PBI40 Tendering of Off-Patent Biologicals and Biosimilars: A Proposal Towards More Sustainable Practices

    Dec 1, 2020, 00:00

  • PCN76 Evaluating Trends In Direct Healthcare Costs In The Last Year Of Life Among Patients With Lung Cancer In Germany

    Dec 1, 2020, 00:00

  • Developments in HTA Processes and Methods

    Dec 1, 2020, 00:00

  • PCN11 Non-Adherence To Oral Treatments In Patients With Multiple Myeloma: Real-World Evidence From A German Claims Data

    Dec 1, 2020, 00:00

  • Alternative Medicine Nutrition - Patient-Centered Research

    Dec 1, 2020, 00:00

  • PCN118 Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands

    Dec 1, 2020, 00:00

  • PCN72 Biomarker Testing to Guide Cost Effective Use of PARPi in Patients with Newly Diagnosed Ovarian Cancer

    Dec 1, 2020, 00:00

  • ML3 Detection of Quality of Life IMPACT in Health-Related Messages in Social MEDIA

    Dec 1, 2020, 00:00

  • PBI32 Fulfilling the Potential of Best-VALUE Biological Medicines in Belgium

    Dec 1, 2020, 00:00

  • PBI20 Evaluation of Published Models in Sickle Cell Disease Against Key Criteria for an Economic Model for a Potentially Curative One-Time Treatment

    Dec 1, 2020, 00:00

  • PCN10 Real-World Hospital Outcomes Versus Clinical Trial Outcomes of Systemic Palliative Treatments for Melanoma STAGE III-IV Patients, with Wild-Type BRAF600 in the Netherlands

    Dec 1, 2020, 00:00

  • Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis (Editor's Choice)

    Dec 1, 2020, 00:00

  • PCN91 Estimating EQ-5D Utilities for Cost-Effectiveness Models Involving Immuno-Oncology Treatments

    Dec 1, 2020, 00:00

  • PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

    Dec 1, 2020, 00:00

  • PCN101 Budget IMPACT Analysis of Treatment-Free Remission (TFR) of Nilotinib Therapy in Chronic Myeloid Leukemia (CML) Patients in the Brazilian Private Healthcare System (BPHS)

    Dec 1, 2020, 00:00

  • IN4 Economic Impact of Routine Childhood Immunization in the 2017 United States Birth Cohort

    Dec 1, 2020, 00:00

  • PCN18 Matching-Adjusted Indirect Comparison (MAIC) of Entrectinib Versus Crizotinib in Patients with ROS1 NON-SMALL CELL LUNG Cancer (NSCLC): An Updated Analysis

    Dec 1, 2020, 00:00

  • PCN102 Healthcare Resource Utilization (HCRU) and Costs with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIS) and Subsequent Chemotherapy Among Patients with LUNG Cancer

    Dec 1, 2020, 00:00

  • PBI47 Innovative Approaches for Patient Access to Gene Therapies in Haemophilia

    Dec 1, 2020, 00:00

  • PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update

    Dec 1, 2020, 00:00

  • PCN115 Economic Evaluation of Artificial Intelligence-Assisted Colonoscopy for Routine Screening of Low- to High-Risk Colorectal Cancer Patients in the United Kingdom

    Dec 1, 2020, 00:00

  • ON2 Assessing the Performance of Landmark Response Analysis to Improve Overall Survival Extrapolation in Nivolumab NSCLC Trials

    Dec 1, 2020, 00:00

  • PCN58 Metastatic Renal Carcinoma Costs in Slovakia: Analysis of Direct and Indirect Costs in 2018

    Dec 1, 2020, 00:00

  • PCN3 IMPACT of COVID-19 on Immunotherapy Utilization in Metastatic NON-SMALL Cell LUNG Cancer

    Dec 1, 2020, 00:00

  • PBI5 An Indirect Comparison of Sustained Remission and FLARE Rates in Responders with NON-Radiographic Axial Spondyloarthritis (NR-AXSPA)

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Economic Evaluation

    Dec 1, 2020, 00:00

  • PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma

    Dec 1, 2020, 00:00

  • PCN89 A Cost-Effectiveness Analysis of Atezolizumab in Combination with Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

    Dec 1, 2020, 00:00

  • PBI46 Cost-Effectiveness of Treatment Sequences Initiating with Risankizumab for the Treatment of Moderate to Severe Psoriasis in Portugal

    Dec 1, 2020, 00:00

  • PCN110 Cost-Utility Analysis of Adjuvant Trastuzumab Emtansine Versus Trastuzumab in Patients with HER2+ EARLY Breast Cancer with Residual Invasive Disease after Neoadjuvant Therapy in Spain

    Dec 1, 2020, 00:00

  • Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income

    Dec 1, 2020, 00:00

  • ML4 Application of Machine Learning Models to Evaluate COVID-19 Related ICU Utilization in a US Population

    Dec 1, 2020, 00:00

  • PBI4 Real World Treatment Patterns of Biologics in a Cohort of Ulcerative Colitis Patients

    Dec 1, 2020, 00:00

  • Medical Technologies Studies

    Dec 1, 2020, 00:00

  • PCN54 Measuring the Economic, Societal, and Organizational IMPACT of Personalized Healthcare in Oncology

    Dec 1, 2020, 00:00

  • PCN70 Cost Effectiveness Analysis of Pembrolizumab in the Treatment of Adults with STAGE III Melanoma and Lymph Node Involvement WHO Have Undergone Complete Resection - the Greek Setting

    Dec 1, 2020, 00:00

  • PCN93 Cost-Effectiveness Analysis of DEB-TACE Compared to Lipiodol-TACE As First LINE Treatment for Unresectable HCC

    Dec 1, 2020, 00:00

  • PCN62 Budget IMPACT Analysis of Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer in Argentina

    Dec 1, 2020, 00:00

  • PCN2 First-LINE Maintenance and Second-LINE Treatment of Advanced or Metastatic Gastric Cancer: A Systematic Review of Literature

    Dec 1, 2020, 00:00

  • PAM7 Preferences of Adults Regarding Personalized Nutrition Interventions: A FOCUS Group Study

    Dec 1, 2020, 00:00

  • PBI29 Does Short-Term Gain Lead to Longer Term Pain ? the Case for Developing a Sustainable Biosimilar Marketplace

    Dec 1, 2020, 00:00

  • PBI55 Patient Preferences for GENE Therapy in Hemophilia: Results from the Paving Threshold Technique Survey

    Dec 1, 2020, 00:00

  • PCN98 Scenarios of Cost-Savings Associated with Oncotype DX® Test - Guided Decisions for Adjuvant Chemotherapy in EARLY Breast Cancer in Germany

    Dec 1, 2020, 00:00

  • Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

    Dec 1, 2020, 00:00

  • PBI23 Cost Saving Opportunity for the Treatment of Psoriasis: The Use of Adalimumab Biosimilars

    Dec 1, 2020, 00:00

  • PBI14 Budget IMPACT Analysis of a Reduced Maintenance Dose of Certolizumab Pegol in Patients with Axial Spondyloarthritis in the United Kingdom

    Dec 1, 2020, 00:00

  • PCN126 A Cost IMPACT Analysis of Clonoseq® As a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic in Multiple Myeloma in Germany

    Dec 1, 2020, 00:00

  • PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France

    Dec 1, 2020, 00:00

  • PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal

    Dec 1, 2020, 00:00

  • PBI35 Local Policies on Biosimilars: Are They Designed to Optimize Use of Freed Resources?

    Dec 1, 2020, 00:00

  • PCN59 Best Supportive Care Costs and Healthcare Use during END-of-Life Care in Terminal Cancer Patients in South Korea: A Retrospective Observational Study from Nationwide Claims Cohort DATA

    Dec 1, 2020, 00:00

  • PCN23 Overall Survival Estimates Adjusting for Treatment Crossover in Patients Previously Untreated with an ALK Inhibitor with ALK+ NSCLC Using DATA from the Alta-1L Clinical Trial

    Dec 1, 2020, 00:00

  • PCN85 An Updated Cost-Utility Analysis in Italian Patients of Entrectinib Compared to Standard of Care in NTRK+ Tumor Agnostic Indication

    Dec 1, 2020, 00:00

  • PA2 Treatment Intensification and Risk of Cardiovascular Events in Insulin-Treated Patients with Type 2 Diabetes; A United Kingdom Retrospective Cohort Study

    Dec 1, 2020, 00:00

  • HTA3 Innovation Rating in Italy: Analysis of 77 Drug/Indication Reports (2017-2020) from AIFA

    Dec 1, 2020, 00:00

  • PCN75 Direct Medical Cost of Breast Cancer in Saudi Arabia

    Dec 1, 2020, 00:00

  • PCN142 Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness

    Dec 1, 2020, 00:00

  • EX2 Structural Uncertainty in Survival Extrapolation: Exploring the IMPACT of FOUR MODEL Averaging Methods and Adjusting for DATA Maturity

    Dec 1, 2020, 00:00

  • PCN130 Modeling Approaches in Cost-Effectiveness Analysis (CEA) of First-Line (1L) Immuno-Oncology (IO) Therapies in Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2020, 00:00

  • PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal

    Dec 1, 2020, 00:00

  • Alternative Medicine Nutrition - Medical Technologies

    Dec 1, 2020, 00:00

  • PBI11 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Atopic Dermatitis in Adolescent Patients in Italy

    Dec 1, 2020, 00:00

  • PCN31 Systematic Review of Efficacy of Programmed Death (PD)-1 and PD-Ligand-1 Inhibitors in the Treatment of NON-SMALL CELL LUNG Cancer

    Dec 1, 2020, 00:00

  • Adherence, Engagement, and Patient Behavior

    Dec 1, 2020, 00:00

  • PCN128 Utility Weight Considerations in Nice Immune Checkpoint Inhibitor Oncology Appraisals

    Dec 1, 2020, 00:00

  • PCN9 Effectiveness of Alectinib in a Real-World US Cohort

    Dec 1, 2020, 00:00

  • PCN13 Comparing Trial Efficacy And Real-World Effectiveness: A Retrospective Study Of Abiraterone In Metastatic Castration Resistant Prostate Cancer Using German claims

    Dec 1, 2020, 00:00

  • PCN90 Economic IMPACT of the NSCLC Molecular Diagnosis in Spain: A Retrospective Analysis of Healthcare Resources Use and Associated Costs from the LUNG-One Study

    Dec 1, 2020, 00:00

  • PBI37 Infliximab and Etanercept Biosimilars and Originators: Learnings from Regional Market Dynamics in Germany

    Dec 1, 2020, 00:00

  • Issues in HEOR - Cardiovascular Disease and Diabetes

    Dec 1, 2020, 00:00

  • PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab ...

    Dec 1, 2020, 00:00

  • PCN56 Brentuximab Vedotin PLUS CHP in Frontline Systemic Anaplastic Large Cell Lymphoma (SALCL): Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Retreatment with Brentuximab Vedotin

    Dec 1, 2020, 00:00

  • PBI48 Overview of GENE Therapy Pricing Policies and Reimbursement Models in the EU-5 (GERMANY, UK, FRANCE, ITALY AND SPAIN)

    Dec 1, 2020, 00:00

  • PCN4 Overall Survival in Post-Menopausal Women with HR+/HER2- Advanced Breast Cancer Receiving a CDK 4 and 6 Inhibitor + Fulvestrant after Progressing on/after Prior Endocrine Therapy: A Fractional Polynomial Network Meta-Analysis

    Dec 1, 2020, 00:00

  • PCN144 The Comparative Pharmacoeconomic Analysis of Using Cabozantinib As Second-LINE Therapy for Adult Patients with Metastatic Renal Cell Carcinoma in Russia

    Dec 1, 2020, 00:00

  • PBI6 Stringent Thresholds of Disease Control Are Associated with Reduced Burden on Paid and Household Work Productivity in Patients with Psoriatic Arthritis during LONG-TERM Treatment with Certolizumab Pegol

    Dec 1, 2020, 00:00
  • «
  • 41 (current)
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »